Monitor Phase 3 enrollment milestones and any FDA feedback on the 505(b)(2) NDA pathway for BIM-IOL System. The BIM-DRS FIH preliminary data in 2027 could expand the addressable market beyond cataract patients.
Drug in focus
SGP drug pipeline →Bimatoprost Drug Pad-IOL System
▲ Bullish Named in this press release- Impact
- Phase
- Phase 3
- Time to market
- Phase 3 trials are enrolling now; topline data expected in 2027. If successful, a 505(b)(2) NDA submission would follow, with potential FDA approval possibly in 2028-2029.
- Next catalyst
- None dated
What to watchWatch for Phase 3 topline readout (expected in 2027, no precise date yet) as the defining binary catalyst. The FIH 4-year data (Oct 2026) de-risks Phase 3 replication risk somewhat, but Phase 3 results will determine whether the 505(b)(2) NDA submission proceeds. Also monitor FDA alignment updates and any accelerated enrollment announcements.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1- T+0 · Nov 12 $33.32entry
- T+1 · 4d ago −1.32%α −0.96% · $32.88
- T+2 · todayOpen
- T+5 · in 2d Pending
- T+20 · in 24d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
SpyGlass Pharma reported Q3 2026 net loss of $24.3M ($0.73 per share), wider than the $9.8M loss in Q3 2025, driven by higher R&D and G&A expenses. The company highlighted Phase 3 enrollment on track for its BIM-IOL System, four-year FIH efficacy data, and the acquisition of AVS for $13M. Cash of $215.8M is expected to fund operations through 2028.
Key Financial Metrics
Key Facts
- Net loss of $24.3M ($0.73 per share) for Q3 2026 vs $9.8M ($4.53 per share) in Q3 2025
- Cash, cash equivalents and short-term investments of $215.8M as of September 30, 2026
- Acquired AVS for ~$13M in cash to secure commercial IOL manufacturing capacity
- Phase 3 enrollment for BIM-IOL System on track, completion expected in 2027
- Four-year FIH data showed 86% of patients off topical drops and 37% mean IOP reduction
- First implantations completed in FIH trial of BIM-DRS, with preliminary data expected in 2027
- R&D expenses $10.0M vs $8.1M; G&A expenses $16.2M vs $3.0M year-over-year
Financial Impact
Net loss widened by $14.5M YoY; cash burn rate increased; $215.8M cash runway through 2028
Risk Factors
- Pre-revenue clinical-stage company with no approved products; relies on successful Phase 3 data and FDA approval
- Net loss and operating expenses are increasing as trials progress; cash burn may accelerate
- Acquisition integration and commercial manufacturing scale-up execution risk
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3401125 |
Track record
9 reports on SGP
4 of 5 bullish or bearish reports moved the stock their way by T+20. Best: +33.66% at T+20 after the Oct 19, 2026 report. 5 of 6 went positive at some point.
Filters
- Nov 12, 20264d ago 8-K Neutral 4/10 No price data
- Nov 11, 20265d ago Press Release Neutral 4/10 Viewing Entry $33.32 Now $32.24 −3.24% settles Dec 11
- Oct 19, 202628d ago 8-K Bullish 6/10 Entry $26.16 Now $32.24 +23.24% settles Nov 17
- Oct 19, 202628d ago Press Release Bullish 7/10 Entry $24.60 to $32.88 Now $32.24 +31.06% ▲ +33.66% +37.12% vs SPY
- Oct 1, 20266w ago 8-K Bullish 6/10 Entry $26.50 to $32.51 Now $32.24 +21.66% ▲ +22.68% +21.98% vs SPY
- Oct 1, 20266w ago Press Release Bullish 6/10 Entry $26.50 to $32.51 Now $32.24 +21.66% ▲ +22.68% +21.98% vs SPY
- May 14, 202626w ago 8-K Neutral 4/10 Entry $23.21 to $18.44 Now $32.24 +38.91% ▼ −20.55% −22.67% vs SPY
- Mar 26, 202633w ago Press Release Bullish 8/10 Entry $22.61 to $23.65 Now $32.24 +42.59% ▲ +4.60% −8.14% vs SPY
- Mar 9, 202636w ago Press Release Bullish 8/10 Entry $27.12 to $21.07 Now $32.24 +18.88% ▼ −22.31% −19.50% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers